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SUMMARY – The aim of this study was clinical testing of the reliability and usability of three-
dimensional (3D) and two-dimensional (2D) ultrasound (US) technology. The ultimate aim and 
purpose of this study was to establish ultrasound methods, standards and protocols for determining 
the volume of any gynecologic organ or tumor. The study included 31 women in reproductive age 
and postmenopause. All patients were examined with a RIC 5-9 3D-endovaginal probe (4.3-7.5 
MHz) on a Voluson® 730 Pro ultrasound device. The volume of myomas was measured by using the 
existing 2D and 3D ultrasound methods on the above mentioned device. All patients underwent 
myomectomy or hysterectomy due to clinically and ultrasonographically diagnosed uterine myomas 
indicating operative intervention. After the operation, the pathologist determined the volume of 
removed myomas by measuring them in a gauge bowl containing water, i.e. using Archimedes’ 
principle (lift), serving as the control group with histopathologic diagnosis. A total of 155 myoma 
volumes were processed on 2D display, 31 myoma volumes were preoperatively measured on 3D dis-
play and 31 myoma volumes were measured by the pathologist. The values of US measurements for 
each US method were expressed as mean value of all measurements of myoma volumes. Statistical 
processing of the results and Student’s t-test for independent samples revealed that the 2nd examined 
US method (measuring of myoma by using an ellipse and the longer tumor diameter) and 4th exa-
mined US method (measuring of myoma by using the longer and shorter tumor diameters together 
with establishing their mean values) in 2D US technique, as well as the 6th examined US method 
in 3D US technique showed no significant measurement differences in comparison with control 
measurement in a gauge bowl containing water (p<0.05), indicating acceptability of the US methods 
for verifying tumor volumes. The standard error in determining the volume of myomas by the above 
US methods varied between 15% and 25%, so it is concluded that these three methods can be used 
in clinical practice to determine tumor volumes, in this case uterine myomas. The 3D MultiPlane 
method proved to be the most reliable method of determining the volume of uterine myomas.
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Introduction
Uterine leiomyomas are the most common benign 
tumors of the female genital system. The prevalence 
of myomas within the female population ranges from 
20% to 50%, depending on the age, parity, ethnic-
ity and diagnostic methods with which their pres-
ence was confirmed1. The real prevalence of myomas 
during pregnancy is unknown and varies from a low 
percentage of 0.1% to 12.5% of all pregnant women2. 
The term ‘myoma’ is used more frequently, but they 
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are also called fibroids. Myomas are responsible for 
at least one-third of admissions to gynecologic wards. 
They are most common in the third and fourth de-
cades of life. Despite various scientific disputes, most 
researchers believe in biochemical activity of myo-
mas. Clinical researches confirmed growth of myo-
mas under conditions of hyperestrogenism. A positive 
metabolic response was established by the action of 
estradiol on estrogenic and progesteronic receptors 
in the cytosol of myometrium and leiomyoma tis-
sues3,4. In the myoma tissue, there are prostaglandin 
E and F receptors5, oxytocin receptors6 and sites at 
which it is associated with the epidermal growth fac-
tor7. In menopause, myomas decrease, become fibrous, 
and some of them calcified. On examination of 50 
women in menopause treated with a combination of 
4 mg estradiol valerate and 200 mg of progesterone 
ethanate, an increase in the number (from 2.2 to 3.5) 
and diameter (from 29.4 to 35 mm) was recorded8. 
During pregnancy, myomas grow due to proliferation 
and hypertrophy of cells. Leiomyomas probably grow 
due to the activity of estrogens on the receptor system 
in tissue cytosol. There is no experimental evidence 
that estrogen causes the emergence of myomas. Leio-
myomas are mostly located in the uterus body and 
rarely encompass uterus ligaments, the lower uterine 
segment or the cervix. Histopathologically, they are 
made of cone bundles of smooth muscle cells similar 
to myometrium constitution. Cell nuclei are oval and 
oblong; mitoses are scarce, whereas there are neither 
giant cells nor anaplasia.
Uterine myomas can be symptom-free and are fre-
quently discovered only at gynecologic examination. 
Symptomatic patients can complain of an increased 
mass in the abdomen, abnormal bleeding, acute or 
chronic pelvic pain, and feeling of pressure in the ab-
domen. The precise mechanism of abnormal vaginal 
bleeding is unknown. Submucous myoma increases 
the surface of the uterus cavity, which peels off and 
consequently causes bleeding. Deligdish and Loewen-
thal describe atrophy of endometrium under a sub-
mucous myoma9. Cyclic endometric changes are not 
possible in the atrophic area. The same authors have 
described hyperplastic changes of endometrium re-
sulting from hyperestrogenism in half of the patients 
having uterine myomas9. Large intramural myomas 
may endanger venal flow in the uterus wall, which 
in turn can cause repeated vaginal bleeding. Pain 
due to a myomatous uterus is described as a feeling 
of weight or dysmenorrhea. Sudden acute pain can be 
caused by myoma necrosis, inflammation of overlay-
ing serosis, or myoma torsion on the stalk. Pain in the 
back or legs arises when an enlarged myoma presses 
the lumbosacral nerve plexus. Disuric pain, reduced 
capacity of the bladder, incontinence, hydronephro-
sis, constipation, and the occurrence of hemorrhoidal 
knots are the possible signs of pressure of an enlarged 
myoma on visceral structures in the small pelvis. Due 
to abundant bleeding, a myomatous uterus frequently 
causes secondary anemia and general weakness. Dur-
ing pregnancy, leiomyomas are usually asymptomatic. 
By examining the dynamics of myoma volume in 107 
women who underwent two or more ultrasound exam-
inations during pregnancy, both reduction (55.1%) and 
increase (44.9%) of tumor volumes were observed10. In 
very rare cases, the clinical course of pregnancy and 
myoma requires surgical intervention11.
Most frequently, a myoma is discovered by biman-
ual palpation of an irregularly increased uterus. In 
84% of cases, the myoma suspected in gynecologic of-
fice is confirmed histologically after surgical interven-
tion; in 30% of women operated on, myomas were not 
diagnosed preoperatively12. By bimanual gynecologic 
examination, it is difficult to differentiate between a 
myoma on the stem and an ovarian tumor. Submu-
cous, intramural or subserous myomas are diagnosed 
operatively by means of hysteroscopy, laparoscopy or 
laparotomy (hysterectomy). Ultrasound, computerized 
tomography and magnetic resonance are diagnostic 
methods with which symptomatic or asymptomatic 
myomas are continuously diagnosed. Due to its sim-
plicity, noninvasiveness, reliability, and a relatively 
low price of examination, ultrasound is the method 
of choice for clinical confirmation of the existence of 
myomas. There are two-dimensional (2D) and three-
dimensional (3D) ultrasound (US) methods combined 
with Doppler visualization of myoma blood vessels 
available. Transvaginal ultrasound is a standard diag-
nostic tool13, and combined with sonohysterography, 
its reliability in diagnosing uterine myoma ranges 
from 98% to 100%14,15. Because of typical imaging on 
the ultrasound screen gray scale, sonographic tumor 
morphology of endometrial cyst, teratoma or leiomy-
oma very rarely differs from the ultimate histologic 
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confirmation16. Based on transvaginal ultrasound ex-
aminations using color Doppler, color Doppler spec-
trometry was employed in an attempt to differentiate 
malignant from benign adnexal neoplasms17. At the 
beginning, this aroused scientific dispute all over the 
world. Today, following many scientific verifications, 
medical profession has concluded that it was impos-
sible and potentially dangerous, based on ultrasound 
Doppler abstraction (RI <0.42; PI <1.00), to go into 
the adventurism of differentially diagnosing benign 
and malignant tumors prior to histopathologic veri-
fication18-22.
Small asymptomatic myomas do not need any 
therapy. It is necessary to closely observe the growth 
of myoma at 4- to 6-month intervals. In women with 
symptomatic myomas, sometimes it is necessary to 
evaluate the existence of endometrial hyperplasia and 
to carry out conservative hormonal therapy with pre-
vious fractional curettage and histopathologic verifi-
cation of the state of endometrium. If after conserva-
tive hormonal therapy there is no improvement and 
symptoms persist, surgical treatment is needed, i.e. 
myomectomy or hysterectomy. Classic indications for 
myomectomy are fast myoma growth, persisting ab-
normal bleeding, pain during lower abdomen palpa-
tion, infertility or asymptomatic myoma bigger that 6 
cm in diameter in women who did not bear children 
nor ended reproduction. Myomectomy as treatment 
of infertility is justified, according to results of some 
studies. This especially holds for abdominal myomec-
tomy, since it has no limitations regarding size and 
number of myomas23. Contraindications for myomec-
tomy are pregnancy, adnexal diseases in an advanced 
stage, malignant small pelvis tumors, and situations 
in which operations lead to reduction of endometrial 
surface and dysfunction of uterus. A surgical dilemma 
between myomectomy and hysterectomy is not easy to 
solve, as stated by Richard TeLinde: “All indications 
and counter indications in the medicine are relative, 
especially when it comes to deciding between a myo-
mectomy and a hysterectomy”24. Indications for hys-
terectomy due to a myomatous uterus are somewhat 
simpler compared to myomectomy. A myomatous 
uterus that by its size corresponds to 12- to 14-week 
pregnancy and growth of myoma in menopause, with 
the mentioned contraindications for myomectomy, 
are the reasons for surgical removal of the uterus. 
Myomectomy and/or hysterectomy, apart from lapa-
rotomy, can also be carried out hysteroscopically or 
laparoscopically. 
Some researchers showed that gestagens favored 
the growth of myomas25,26. The mitotic activity of 
leiomyomas is greater in an early luteal phase than in 
the follicular phase27. The RU 486 antiprogesterone 
slows down the growth of myomas and is an indica-
tor of biochemical role in the emergence and growth 
of fibroids28. Due to this information, after applying 
GnRH agonists in conservative therapy of myomas, 
danazol was introduced as a synthetic steroid with 
antigonadotropin characteristics, with biochemical 
affinity for cytoplasmic receptors and influence on 
steroidogenesis of the ovary and suprarenal gland29. 
Administration of danazol after GnRH agonists re-
duced the volume of fibroids by 30% in comparison 
with control group30. 
Selective embolization of uterine artery represents 
an alternative method of treating myomas in patients 
in whom abundant bleeding or surgical procedure are 
to be avoided31,32. Although pregnancies after selec-
tive myoma embolization have been described33, this 
method can be dangerous in women who had no chil-
dren due to consequent uterine fibrosis and infertil-
ity.
The aim of this paper is to evaluate the reliability 
of diagnostic possibilities of ultrasound in determin-
ing myoma volumes. Determining the most reliable 
ultrasound method was only a temporary aim. The 
ultimate one, as well as the scope of this study, was 
to establish ultrasound methods and protocols for 
determining the volume of any gynecologic organ or 
tumor. Also, one of the aims was to clinically test the 
reliability and usability of 3D ultrasound technology 
as opposed to conventional 2D real-time ultrasound. 
Patients and Methods
The study included 31 women in reproductive age 
and postmenopause. All patients were examined with 
a 4.3-7.5 MHz RIC 3D endovaginal multi frequency 
probe on a Voluson® 730Pro (General Electric Medi-
cal Systems Kretztechnic GmbH & Co. OHG 2003, 
Austria) ultrasound device. The myoma volumes were 
measured by using the existing 2D and 3D ultrasound 
methods that make up part of the software system of 
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this ultrasound device. Of ultrasound methods for 
myoma volumes, five 2D methods and one 3D meth-
od were used. 
A. Measuring the volume of ovoid body by using 
three diameters: 2D ultrasound program of measur-
ing the volume of ovoid bodies with three diameters 
is the most frequent one in gynecologic practice. First 
must be measured the D1 distance between two op-
posed poles in the longest transverse myoma section. 
Then, tumor width or D2 anterior-posterior diameter 
is determined through the center of tumor in verti-
cal display compared with the preceding section. The 
width or D3 transverse diameter is vertical length on 
the anterior-posterior diameter or D2 (Fig. 1). The ul-
trasound device software automatically measures the 
volume according to the formula for the volume of el-
lipsoid:
B. Measuring ovoid volumes by using the longer di-
ameter and an ellipse: the volume of ellipsoid in GE 
Voluson 730 Pro software is determined from two 
mutually vertical ellipse axes and one distance (Fig. 
2). The formula for determining the volume of body 
by using one diameter and ellipse reads as follows: 
whereby: 
The above formula that has not been found in relevant 
expert literature represents an integral part of 730 
Voluson Pro devices. It was supplied by the courtesy 
of Mr. Michael Heinziger from GE Medical Systems 
Kretztechnik GmbH & Co. OHG, Austria.
C. Measuring ovoid volumes by using the shorter 
diameter and an ellipse: on the same ultrasound dis-
play, the myoma volume is determined by using the 
longer diameter and an ellipse (description B) and 
then, by using the shorter diameter, which is verti-
cal and passes through the center of the longer one, 
the volume of a myoma numerically different from 
the method described under section B is determined 
(Fig. 2). For measuring ellipsoid volumes by using the 
shorter diameter and ellipse, the same formula and 
description is valid as for measuring the volume by 
using the longer diameter and ellipse. 
D. Measuring ovoid volumes by using the longer and 
shorter diameter with determination of their mean val-
ues: it is possible to calculate the volume of a spherical 
body if its diameter is known or using the formula: 
The same formula represents an integral part of the 
software of the above mentioned ultrasound device. 
In our research, a methodology of determining the 
longer diameter of D1 ellipsoid and V1 volume and, 








2Db = 3Dc =
3
4 3πrV =
Fig. 1.  Measuring myoma by using three diameters. Fig. 2. Measuring myoma volume by using a longer or 
shorter diameter and an ellipse.
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ellipsoid and V2 volume, was used (Fig. 3). Finally, 
both volumes were added and divided by two:
E. Measuring ovoid volumes by using one ellipse: 
ellipsoid volume in the software of the device can be 
determined by rotating the ellipse around an axis (on 
the ultrasound device display it is shown as a dotted 
ellipse line) (Fig. 4). The formula for determining the 
volume of ovoid body from one ellipse is:
where    and 
Neither this formula was found in relevant expert lit-
erature, but it is an integral part of the mentioned ul-
trasound device software. It was also supplied by the 
courtesy of Mr. Michael Heinziger from GE Medical 
Systems Kretztechnik GmbH & Co. OHG, Austria.
F. Measuring ovoid volumes by using 3D presen-
tation and 3D MultiPlane methodology: the volume 
of ovoid bodies can be measured by means of ultra-
sound technology contained in the software of this 
ultrasound device. For measuring the volume of ovoid 
body by 3D MultiPlane technology, display or stor-
ing ultrasound pictures in 3D X, Y and Z systems is 
necessary. The ovoid body (myoma) is shown at the in-
tersection of the longest axis. The moving of one end 
(pole) of the ovoid body toward the opposite end (pole) 
takes place simultaneously at all three ultrasound X, Y 
and Z intersections. At the intersection with the lon-
gest axis of ovoid body, the motion of one end towards 
another one in one of the remaining two intersections 
of the coordinate system is controlled. By means of 
‘slice methodology’, the outlines of the ovoid body are 
drawn, i.e. the surface of transverse intersection at 
each point of opposite ends is determined. The mul-
tiplication of all surfaces and distances between the 
two opposite ends of ovoid bodies gives the ellipsoid 
volume. Here, the principle of measuring consists of 
the so-called ‘fan scan’ with a basic demand that the 
2D display is in a vivid picture as a central plane for 
orientation inside the volume depicted. A multisec-
tional, multiplane 3D display is, actually, depiction of 
volume in three mutually vertical intersections (Figs. 
5 and 6).
All patients underwent operative intervention, 
myomectomy or hysterectomy, due to clinically and 
ultrasonographically diagnosed uterine myomas that 
indicated the necessity of operative intervention. The 
myoma volume was preoperatively measured with 
the ultrasound techniques described. Postoperatively, 
the pathologist determined the volume of the same 
myomas, now in a test bowl using Archimedes’ prin-
ciple. Simultaneously, it served as the control group 
or histopathology group in this study. Archimedes’ 
principle is a law of physics stating that the upward 
force (buoyancy) exerted on a body immersed in a 
fluid is equal to the weight of the amount of fluid the 
body displaces. In other words, an immersed object is 
buoyed up by a force equal to the weight of the fluid 
( ) ( )
2
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Fig. 3. Measuring myoma volume by using a longer and 
shorter diameter.
Fig. 4. Measuring myoma volume by using an ellipse. 
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it actually displaces. The volume of body determined 
in a gauge bowl containing water is the most correct 
volume. 
The values of ultrasound measurements of myo-
mas for each ultrasound method were expressed as 
the mean values of all measurements of myoma vol-
umes. The mean values of myoma volumes measured 
by ultrasound were compared to the real mean values 
of myoma volumes measured by using Archimedes’ 
principle, which represented control histopathology 
group. All values acquired by measuring myoma vol-
umes are depicted in tables and figures. On statisti-
cal data processing, Student’s t-test for independent 
samples was used. It is one of mostly used statistical 
tests. It is counted as one of parametrical statistical 
tests and is used for comparing two sets of data on the 
same sample, i.e. for testing quantitative variables. 
Results
The study included 31 patients of reproductive age 
and in postmenopause. The methods used in the study 
were 5 methods of determining myoma volume on 
2D and one on 3D ultrasound displays. Postoperative 
measurements of the myoma volumes in a test bowl 
with water at pathology department served as control 
group. Reliability of determining the myoma volume 
by the ultrasound techniques was tested by use of di-
agnostics and preoperative measurements. The values 
measured by each ultrasound method were sorted into 
appropriate groups, including respective control his-
topathology group. In total, 155 myoma volumes in 
2D ultrasound display and 31 myoma volumes in 3D 
ultrasound display were determined prior to operative 
intervention, as well as 31 determinations of the real 
myoma volumes by the pathologist. The values of my-
oma ultrasound measurements for each US method 
were expressed as the mean values of all measurements 
of myoma volumes. Ultrasonographically measured 
mean values of all measurements of myoma volumes 
were compared mutually as well as with the real mean 
values of myoma volumes recorded by the pathologist 
using Archimedes’ law, which represented the control 
histopathology group. The values of myoma volume 
Fig. 5. and Fig. 6. Measuring myoma volume by a 3D display and 3D Multiplane methodology.
Fig. 7.  Mean values of myoma volumes measured in 2D 
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measurements are shown in Table 1 and Figure 7. 
The mean values of deviations for each US method of 
volume measuring are shown in Tables 2 and 3 and 
Figure 8. Statistical data processing was done by use 
of Student’s t-test for independent samples, t-value 
and statistical significance of difference. P-value was 
calculated for each US method versus control histopa-
thology group (Fig. 9). 
The results obtained suggested the following con-
clusions: 1st US method of myoma volume measure-
ment versus control histopathology to be unaccept-
able for clinical use (t=0.948, p>0.05); 2nd ultrasound 
Table 1. Numerical display of myoma volume measurements in two-dimensional and three-dimensional ultrasound 
displays of their mean values and comparison with control histopathology group
V1 V2 V3 V4 V5 V6 3D Histopathology
131.47 156.02 117.13 151.45 121.37 221.98 160.00
262.98 354.17 272.91 338.73 216.14 275.38 360.00
140.19 158.27 131.08 153.27 142.54 176.92 120.00
22.51 34.17 24.16 32.16 24.21 30.15 30.00
21.70 26.08 25.74 25.91 24.54 27.12 24.00
62.30 80.76 59.19 79.56 60.97 77.01 80.00
93.34 136.50 106.39 115.96 124.36 117.01 90.00
133.40 212.52 154.73 198.02 182.94 115.21 100.00
289.00 339.21 258.56 337.42 258.42 297.93 300.00
13.57 14.20 9.80 17.96 13.86 13.41 18.00
31.68 56.93 31.64 59.97 33.48 32.13 30.00
50.83 57.85 36.18 57.90 41.05 57.05 80.00
40.63 52.46 41.38 51.42 43.40 55.90 80.00
31.61 40.21 26.45 36.89 27.58 35.34 43.00
23.64 27.80 21.18 22.84 24.94 33.88 40.00
8.45 8.88 6.70 8.32 8.64 7.28 10.00
94.13 109.33 91.22 113.67 98.75 130.78 110.00
119.33 155.39 132.76 146.84 136.72 119.39 150.00
45.90 48.93 39.24 54.68 47.35 40.98 55.00
16.55 23.98 18.24 22.69 17.90 19.90 30.00
42.15 92.25 58.66 96.73 56.79 90.81 70.00
54.76 82.16 52.26 81.92 54.39 67.04 85.00
32.76 34.44 34.02 33.91 35.55 42.64 40.00
57.25 76.73 53.83 74.80 59.29 82.57 72.00
50.55 69.62 49.60 64.73 45.99 60.91 55.00
114.89 149.63 121.28 141.85 121.63 151.90 160.00
10.31 25.97 10.41 24.94 10.98 20.60 20.00
54.54 61.42 49.45 60.26 53.62 72.42 78.00
32.92 39.92 31.93 37.25 32.11 37.45 31.00
29.68 34.10 29.20 33.27 33.09 34.30 35.00
21.67 22.42 16.62 22.04 16.87 31.41 30.00
68.86 89.75 68.13 87.01 69.98 83.12 83.42
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method of myoma volume measurement versus control 
histopathology group to be acceptable for clinical use 
(t=0.036, p<0.05); 3rd ultrasound method of myoma 
volume measurement versus control histopathol-
ogy group to be unacceptable for clinical use (t=0.40, 
p>0.05); 4th ultrasound method of myoma volume 
measurement versus control histopathology group to 
be acceptable for clinical use (t=0.01, p<0.05); 5th ul-
trasound method of myoma volume measurement ver-
sus control histopathology group to be unacceptable 
for clinical use (t=0.185, p>0.05); and 6th ultrasound 
method of myoma volume measurement by means of 
3D US presentation with 3D Multiplane method ver-
sus control histopathology group to be acceptable for 
clinical use (t=0.01, p<0.05).
Discussion
In the present study, the US possibilities of myoma 
volume measurement carried out by means of 2D US 
technology in five variations and one type of 3D US 
technology were assessed. In the literature, US mea-
surement of the volume of polycystic ovaries by 2D 
technology is most frequently described34-38, so this 
study is unique and represents significant contribu-
tion to medical profession and daily clinical routine. 
Measuring the volume of some organs with US meth-
ods exists and has been described in the literature. 
Orsini et al. have published one of the first studies 
dealing with the problem of measur-
ing the volume of polycystic ovaries. It 
was concluded that there was a signifi-
cant difference between healthy women 
with normal ovaries and women with 
polycystic ovary syndrome, particularly 
regarding the value of ovary volume, 
the volume of uterus, and the size of 
both these volumes34. It was a pioneer 
research in which US techniques of 
measuring the volume of female repro-
ductive organs were defined. The devel-
opment of US technology has enabled 
3D measurement of the volume of ovoid 
Table 2. Mean values of aberrations for each ultrasound 
method of measurement
Vol. I Vol. II Vol. III Vol. IV Vol. V Vol. VI
0.23688 0.22324 0.27360 0.20536 0.26054 0.17588
Table 3. Numerical display of ultrasound methods with lowest aberrations 
on determining myoma volume
 Frequency Percent Valid percent
Cumulative
 percent
Method 1 2 6.5 6.5 6.5
 2 5 16.1 16.1 22.6
 3 4 12.9 12.9 35.5
 4 8 25.8 25.8 61.3
 5 1 3.2 3.2 64.5
 6 11 35.5 35.5 100.0
Total 31 100.0 100.0  
Fig 8.  Numerical display of the lowest aberrations for 
each ultrasound method.
Fig. 9. Cumulative display of errors in determining vol-
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bodies. Recently, this is presented by papers on mea-
suring the volume and weight of single structures and 
organs, calculated by computing methods. A study 
by Rovio et al. is important for having compared the 
formulas for preoperative evaluation of the weight of 
myomatous uterus in 12 women with symptomatic 
myomas39. It was concluded that a geometric formula 
that combines an ellipsoid and a cylinder in com-
parison with a formula combining only an ellipsoid 
makes possible better preoperative evaluation of the 
weight of myomatous uterus. Accordingly, it is clear 
that preoperative evaluation of the volume, but also 
of the weight acquired by calculating measures of 2D 
and 3D displays, gives significantly better information 
for planning the strategy of treatment. The technology 
used in 3D US presentations is called VOCAL (Vol-
ume Calculation or Virtual Organ Computer-aided 
Analysis). In our research of myoma volume measure-
ment, VOCAL was not used as it is an integral part of 
Voluson 730 Pro ultrasound device. The development 
of medical technology brings new diagnostic and 
therapeutic standards. On clinical evaluation of the 
spread of any gynecologic malignant neoplasia, the 
value of the primary tumor volume is a very important 
factor in choosing the method of treatment. 
Conclusion
The information presented makes the first step 
towards new diagnostic standards in the use of vol-
umetry in daily US diagnostic practice, whether an 
organ or tumor is assessed. Apart from the US (study 
groups) and pathologic (control group) measurements, 
the research presented had a scientific dimension be-
cause, with statistical processing, it determined the 
US methods that yielded measurements closest to the 
real tumor volumes. The standard error in the 2nd and 
4th US study groups and in the 6th 3D US study groups 
varied between 15% and 25% compared with the con-
trol measurement in a gauge bowl containing water. 
This indicates that the mentioned methods could be 
used in clinical practice. Only aberrations from the 
real values measured in the gauge bowl can define 
which US methods are best for measuring myoma 
volumes. More expensive US technologies, such as 
3D US method of examination, are at the same time 
less accessible to patients because they are reserved for 
gynecologic departments and well-equipped tertiary 
institutions. By introducing 3D US technology in ev-
eryday clinical practice, the very top of noninvasive di-
agnostics might be reached. On comparing the meth-
ods of US examination to one another, it is necessary 
to stress that 3D US technology offers better results in 
case of unclear and complicated structures. To the ex-
amining physician, especially one with clinical expe-
rience with 2D ultrasound, it helps in diagnosing the 
smallest of neoplasms and abnormalities. 3D US has 
improved volumetry and made it more precise with a 
small percentage of errors. Everyday advances in US 
technology create new possibilities of diagnostic ap-
proaches and, connected with this, timely therapeutic 
solutions. It is known that the change in diameter of 
ovoid or oval bodies from 4 to 5 cm in 2D is a 100% 
volume difference in 3D system. These are very im-
portant data in current gynecologic practice, where 
various malignant tumors are found. This difference 
in size, even if it is only one centimeter, may mean 
complete healing or the loss of battle for life. Conse-
quently, one of the long-term purposes of this study 
should be the use of the experiences of measuring 
myoma volume as well as other gynecologic tumors 
in the diagnosis and treatment of malignant diseases 
of the female reproductive system. Finally, this study 
proved that, in the absence of expensive and modern 
3D US devices, tumor volume can be measured with 
high precision by using 2D US devices. The highest 
precision can be achieved if the 2nd or 4th method of 
tumor volume measurement is used, so that when 
measuring, the longer diameter of the tumor is mea-
sured and around the same tumor an ellipse is set; in 
the second option, the measured longer and shorter 
diameter of the myoma are taken into account. 
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Sažetak
MJERENJE VOLUMENA MIOMA DVODIMENZIONALNIM I TRODIMENZIONALNIM 
ULTRAZVUČNIM PRIKAZOM I USPOREDBA S PATOHISTOLOŠKIM NALAZOM
N. Živković, K. Živković, A. Despot, J. Paić i A. Zelić
Cilj ovoga istraživanja je bio klinički testirati pouzdanost i upotrebljivost trodimenzionalne (3D) i dvodimenzionalne 
(2D) ultrazvučne (UZ) tehnologije. Krajnji cilj i smisao ovoga istraživanja je bio ustanoviti ultrazvučne metode, standar-
de i protokole za određivanje volumena bilo kojeg ginekološkog organa ili tumora. Istraživanje je obuhvatilo 31 ženu u 
reproduktivnoj dobi i poslijemenopauzi. Sve bolesnice su pregledane 3D endovaginalnom multifrekventnom sondom (4,3-
7,5 MHz) RIC 5-9 na ultrazvučnom aparatu Voluson® 730 Pro. Volumeni mioma su se mjerili upotrebljavajući 2D i 3D 
ultrazvučne metode koje su sastavni dio softverskog sustava navedenog ultrazvučnog aparata. Sve bolesnice su podvrgnute 
miomektomiji ili histerektomiji zbog klinički i ultrazvučno dijagnosticiranih mioma maternice koji su indicirali operacij-
ski zahvat. Kod istih bolesnica poslijeoperacijski je patolog odredio volumen odstranjenih mioma mjerenjem u baždarenoj 
posudi s vodom, tj. primjenom Arhimedova zakona (uzgon), a to je bila kontrolna skupina ili patohistološki dijagnosticira-
na skupina u ovom istraživanju. Ukupno je bilo određeno 155 volumena mioma u 2D ultrazvučnom prikazu i 31 mjerenje 
volumena mioma u 3D ultrazvučnom prikazu prije operacijskog zahvata i 31 mjerenje stvarnog volumena mioma koje je 
proveo patolog. Vrijednosti UZ mjerenja volumena mioma za svaku pojedinu UZ metodu izražene su kao srednje vrijed-
nosti svih mjerenja volumena mioma. Statističkom obradom rezultata i primjenom Studentova t-testa za nezavisne uzorke 
utvrđeno je da 2. ispitivana UZ metoda (mjerenje volumena mioma upotrebom elipse i duljeg promjera tumora) i 4. ispiti-
vana UZ metoda (mjerenje volumena mioma upotrebom duljeg i kraćeg promjera tumora uz određivanje njihovih srednjih 
vrijednosti) u 2D UZ tehnici te 6. ispitivana UZ metoda u 3D UZ tehnici nisu pokazale značajnost razlike prikazanih 
mjerenja u odnosu na kontrolna mjerenja u baždarenoj posudi s vodom (p<0,05), što upućuje na prihvatljivost navedenih 
UZ metoda za procjenu volumena tumora. Veličina pogreške pri izračunu volumena mioma kod prethodno spomenutih 
UZ metoda varirala je između 15% i 25%, pa se zaključuje da se tri navedene UZ metode mogu rabiti u kliničkoj praksi 
pri pokušaju izračuna volumena tumora, u ovom slučaju mioma maternice. Trodimenzionalna UZ metoda 3D MultiPlane 
najpouzdanija je metoda za određivanje volumena mioma maternice.
Ključne riječi: Fibroid maternice; Ultrazvuk; 3-D slikovne tehnike; Volumen tumora; Histopatologija

